JPRN-jRCT2031230256进行中（未招募）3 期
A Phase III, Single-Arm, Open-Label Study to Evaluate the Safety,Pharmacokinetics, Anti-Drug Antibody, and Anti-RSV Neutralizing Antibody Following Administration of 2 Doses of Nirsevimab Given 5 to 6 Months Apart in Infants with Congenital Heart Disease, Chronic Lung Disease, Immunocompromise, Down Syndrome, or Born Pre-Term in Japan - JUBILUS
jRCT Inquiries IQVIA contact person0 个研究点目标入组 33 人开始时间: 2023年7月26日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 <= 12month old（—）
- 性别
- All
入选标准
- •1.Written informed consent and any locally required authorization obtained from the participant's parent(s)/legally authorized representative(s) before performing any protocol-related procedures, including screening evaluations
- •2.Japanese infants of <=12 months of age eligible to receive palivizumab in accordance with national or local guidelines and those who must meet at least one of the following conditions at the time of informed consent.
- •(a)Immunodeficiency
- •(b)Chronic Lung Disease
- •(c)Congenital Heart Disease
- •(d)Down syndrome
- •(e)Born pre-term <=28 wks Gestation age and aged <=12 months, or born pre-term >28 wks and <=35 wks Gestation age and aged <=6 months
- •3.The participant's parent(s)/legally authorized representative(s) can understand and comply with the requirements of the protocol including follow-up visits as judged by the investigator.
- •4.The participant is available to complete the follow-up period for approximately 19 months, which will be approximately 1 year after receipt of 2nd dose of nirsevimab.
排除标准
- •1.Requirement for mechanical ventilation, extracorporeal membrane oxygenation, continuous positive airway pressure (CPAP), or other mechanical respiratory or cardiac support at the time of enrollment
- •2.A current, active RSV infection at the time of screening and investigational product administration
- •3.Any fever (>=100.4F [>=38.0C], regardless of route) or acute illness at the time of prior to investigational product administration
- •4.Any serious concurrent medical condition (except those resulting in an immune deficiency condition), including:
- •(a)Known renal impairment
- •(b)Known hepatic dysfunction including known or suspected active or chronic hepatitis infection
- •(c)Any seizure disorder or evolving or unstable neurological condition
- •5.Anticipated cardiac surgery within 5-6 months after enrollment
- •6.Prior history of a suspected or actual acute life-threatening event
- •7.Receipt or intended use of palivizumab in the current enrollment season
- •8.Any known allergy or history of allergic reaction to any component of nirsevimab
- •9.Any known allergy or history of allergic reaction to immunoglobulin products, blood products, or other foreign proteins
- •10.Concurrent enrollment in another interventional study, or prior receipt of any investigational agent
- •11.Anticipated survival of less than 1 year at the time of informed consent
- •12.Any condition that, in the opinion of the investigator, would interfere with the evaluation of the investigational product or interpretation of study results
- •13.Children of employees of the Sponsor, clinical study site, or any other individuals involved with the conduct of the study, or immediate family members of such individuals
研究者
相似试验
进行中（未招募）
1 期
An Open-Label, Single-Arm Phase III Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected PatientsEUCTR2011-004097-29-BEJanssen R&D Ireland100
尚未招募
3 期
A Phase 3 Study of Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with (HR+), (HER2)-Negative Breast Cancer.CTRI/2024/07/070855Tolmar, Inc.
进行中（未招募）
1 期
Phase 2/3 study of Remdesivir in patients from birth to <18 years old with COVID-19Coronavirus disease 2019 (COVID-19)MedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-001803-17-GBGilead Sciences Inc.52
进行中（未招募）
1 期
Phase 2/3 study of Remdesivir in patients from birth to <18 years old with COVID-19EUCTR2020-001803-17-ITGILEAD SCIENCES INCORPORATED52
进行中（未招募）
1 期
A study to examine the efficacy of KRN23 on bone qualityEUCTR2015-001775-41-FRltragenyx Pharmaceutical Inc.10